[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614481":3},{"organization":4,"armGroups":7,"interventions":38,"overallOfficials":44,"centralContacts":58,"locations":64,"responsibleParty":296,"collaborators":44,"id":298,"slug":299,"hasResults":300,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":300,"sex":306,"minAge":307,"maxAge":44,"enrollmentInfo":308,"targetDuration":44,"studyType":311,"phases":312,"briefSummary":314,"conditions":315,"keywords":317,"overallStatus":67,"whyStopped":44,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":331},{"fullName":5,"class":6},"Protalix","INDUSTRY",[8,15,20,24,28,34],{"label":9,"type":10,"description":11,"interventionNames":12},"E4W with placebo-MTX","EXPERIMENTAL","IV infusion of PRX-115 every 4 weeks (E4W) for a total of 6 doses with placebo-MTX",[13,14],"Biological: PRX-115","Other: Placebo-Methotrexate",{"label":16,"type":10,"description":17,"interventionNames":18},"E4W with MTX","IV infusion of PRX-115 every 4 weeks (E4W) for a total of 6 doses with MTX",[13,19],"Drug: Methotrexate (MTX)",{"label":21,"type":10,"description":22,"interventionNames":23},"E6W with MTX","IV infusion of PRX-115 every 6 weeks (E6W) for a total of 4 doses with MTX",[13,19],{"label":25,"type":10,"description":26,"interventionNames":27},"E8W with MTX","IV infusion of PRX-115 every 8 weeks (E8W) for a total of 3 doses with MTX",[13,19],{"label":29,"type":30,"description":31,"interventionNames":32},"placebo E4W","PLACEBO_COMPARATOR","infusion of PRX-115 placebo every 4 weeks (E4W) for a total of 6 doses with placebo-MTX",[33,14],"Other: PRX-115 placebo",{"label":35,"type":30,"description":36,"interventionNames":37},"placebo E6W","IV infusion of PRX-115 placebo every 6 weeks (E6W) for a total of 4 doses with placebo-MTX",[33,14],[39,45,50,54],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"BIOLOGICAL","PRX-115","intravenous (IV) infusion",[16,9,21,25],null,{"type":46,"name":47,"description":48,"armGroupLabels":49,"otherNames":44},"DRUG","Methotrexate (MTX)","Oral MTX 15 mg weekly",[16,21,25],{"type":51,"name":52,"description":42,"armGroupLabels":53,"otherNames":44},"OTHER","PRX-115 placebo",[29,35],{"type":51,"name":55,"description":56,"armGroupLabels":57,"otherNames":44},"Placebo-Methotrexate","Oral Placebo-MTX weekly",[9,29,35],[59],{"name":60,"role":61,"phone":62,"phoneExt":44,"email":63},"Head of Clinical Development","CONTACT","+972-4-902-8100","info@protalix.com",[65,79,89,99,108,117,126,135,141,147,156,162,171,179,189,199,209,219,228,238,244,250,255,261,267,278,287],{"facility":66,"status":67,"city":68,"state":69,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":44},"Applied Research Center of Arkansas","RECRUITING","Little Rock","Arkansas","72205","United States","US",{"type":74,"coordinates":75},"Point",[76,77],-92.28959,34.74648,{"lat":77,"lon":76},{"facility":80,"status":67,"city":81,"state":82,"zip":83,"country":71,"countryCode":72,"cosmosGeoPoint":84,"geoPoint":88,"contacts":44},"Triwest Research Associates Llc","El Cajon","California","91910",{"type":74,"coordinates":85},[86,87],-116.96253,32.79477,{"lat":87,"lon":86},{"facility":90,"status":67,"city":91,"state":92,"zip":93,"country":71,"countryCode":72,"cosmosGeoPoint":94,"geoPoint":98,"contacts":44},"Clinical Research of West Florida, Inc.","Clearwater","Florida","33765",{"type":74,"coordinates":95},[96,97],-82.8001,27.96585,{"lat":97,"lon":96},{"facility":100,"status":67,"city":101,"state":92,"zip":102,"country":71,"countryCode":72,"cosmosGeoPoint":103,"geoPoint":107,"contacts":44},"Accel Research Sites - Deland Clinical Research Unit","DeLand","32720",{"type":74,"coordinates":104},[105,106],-81.30312,29.02832,{"lat":106,"lon":105},{"facility":109,"status":67,"city":110,"state":92,"zip":111,"country":71,"countryCode":72,"cosmosGeoPoint":112,"geoPoint":116,"contacts":44},"ICR Sites East","Doral","33125",{"type":74,"coordinates":113},[114,115],-80.35533,25.81954,{"lat":115,"lon":114},{"facility":118,"status":67,"city":119,"state":92,"zip":120,"country":71,"countryCode":72,"cosmosGeoPoint":121,"geoPoint":125,"contacts":44},"Qway Research","Hialeah","33010",{"type":74,"coordinates":122},[123,124],-80.27811,25.8576,{"lat":124,"lon":123},{"facility":127,"status":67,"city":128,"state":92,"zip":129,"country":71,"countryCode":72,"cosmosGeoPoint":130,"geoPoint":134,"contacts":44},"Bioclinical Research Alliance, Inc","Miami","33155",{"type":74,"coordinates":131},[132,133],-80.19366,25.77427,{"lat":133,"lon":132},{"facility":136,"status":67,"city":128,"state":92,"zip":137,"country":71,"countryCode":72,"cosmosGeoPoint":138,"geoPoint":140,"contacts":44},"D&H National Research Centers (North Miami)","33169",{"type":74,"coordinates":139},[132,133],{"lat":133,"lon":132},{"facility":142,"status":67,"city":128,"state":92,"zip":143,"country":71,"countryCode":72,"cosmosGeoPoint":144,"geoPoint":146,"contacts":44},"Well Pharma Medical Research Group","33173",{"type":74,"coordinates":145},[132,133],{"lat":133,"lon":132},{"facility":148,"status":67,"city":149,"state":92,"zip":150,"country":71,"countryCode":72,"cosmosGeoPoint":151,"geoPoint":155,"contacts":44},"Conquest Research - Lake Nona","Orlando","32832",{"type":74,"coordinates":152},[153,154],-81.37924,28.53834,{"lat":154,"lon":153},{"facility":157,"status":67,"city":149,"state":92,"zip":158,"country":71,"countryCode":72,"cosmosGeoPoint":159,"geoPoint":161,"contacts":44},"Combined Research Orlando Phase I-IV","32897",{"type":74,"coordinates":160},[153,154],{"lat":154,"lon":153},{"facility":163,"status":67,"city":164,"state":92,"zip":165,"country":71,"countryCode":72,"cosmosGeoPoint":166,"geoPoint":170,"contacts":44},"New Horizons Research","Palmetto Bay","33176",{"type":74,"coordinates":167},[168,169],-80.32477,25.62177,{"lat":169,"lon":168},{"facility":90,"status":67,"city":172,"state":92,"zip":173,"country":71,"countryCode":72,"cosmosGeoPoint":174,"geoPoint":178,"contacts":44},"Tampa","33606",{"type":74,"coordinates":175},[176,177],-82.45843,27.94752,{"lat":177,"lon":176},{"facility":180,"status":67,"city":181,"state":182,"zip":183,"country":71,"countryCode":72,"cosmosGeoPoint":184,"geoPoint":188,"contacts":44},"Centricity Research - Columbus Georgia Multispecialty","Columbus","Georgia","31904",{"type":74,"coordinates":185},[186,187],-84.98771,32.46098,{"lat":187,"lon":186},{"facility":190,"status":67,"city":191,"state":192,"zip":193,"country":71,"countryCode":72,"cosmosGeoPoint":194,"geoPoint":198,"contacts":44},"Quest Research Institute","Farmington Hills","Michigan","48334",{"type":74,"coordinates":195},[196,197],-83.37716,42.48531,{"lat":197,"lon":196},{"facility":200,"status":67,"city":201,"state":202,"zip":203,"country":71,"countryCode":72,"cosmosGeoPoint":204,"geoPoint":208,"contacts":44},"Altoona Center for Clinical Research","Duncansville","Pennsylvania","16635",{"type":74,"coordinates":205},[206,207],-78.4339,40.42341,{"lat":207,"lon":206},{"facility":210,"status":67,"city":211,"state":212,"zip":213,"country":71,"countryCode":72,"cosmosGeoPoint":214,"geoPoint":218,"contacts":44},"Pioneer Research Solutions Inc","Houston","Texas","77099",{"type":74,"coordinates":215},[216,217],-95.36327,29.76328,{"lat":217,"lon":216},{"facility":220,"status":67,"city":221,"state":212,"zip":222,"country":71,"countryCode":72,"cosmosGeoPoint":223,"geoPoint":227,"contacts":44},"Mt. Olympus Medical Research, LLC - Sugar Land","Sugar Land","77479",{"type":74,"coordinates":224},[225,226],-95.63495,29.61968,{"lat":226,"lon":225},{"facility":229,"status":67,"city":230,"state":44,"zip":231,"country":182,"countryCode":232,"cosmosGeoPoint":233,"geoPoint":237,"contacts":44},"Aleksandre Aladashvili Clinic LLC, Georgia","Tbilisi","0102","GE",{"type":74,"coordinates":234},[235,236],44.83412,41.69143,{"lat":236,"lon":235},{"facility":239,"status":67,"city":230,"state":44,"zip":240,"country":182,"countryCode":232,"cosmosGeoPoint":241,"geoPoint":243,"contacts":44},"Tbilisi Heart and Vascular Clinic Ltd , Georgia","0159",{"type":74,"coordinates":242},[235,236],{"lat":236,"lon":235},{"facility":245,"status":67,"city":230,"state":44,"zip":246,"country":182,"countryCode":232,"cosmosGeoPoint":247,"geoPoint":249,"contacts":44},"Mediclub Georgia","0160",{"type":74,"coordinates":248},[235,236],{"lat":236,"lon":235},{"facility":251,"status":67,"city":230,"state":44,"zip":246,"country":182,"countryCode":232,"cosmosGeoPoint":252,"geoPoint":254,"contacts":44},"Tbilisi Institute of Medicine, Georgia",{"type":74,"coordinates":253},[235,236],{"lat":236,"lon":235},{"facility":256,"status":67,"city":230,"state":44,"zip":257,"country":182,"countryCode":232,"cosmosGeoPoint":258,"geoPoint":260,"contacts":44},"Georgian-Dutch Hospital, Georgia","0172",{"type":74,"coordinates":259},[235,236],{"lat":236,"lon":235},{"facility":262,"status":67,"city":230,"state":44,"zip":263,"country":182,"countryCode":232,"cosmosGeoPoint":264,"geoPoint":266,"contacts":44},"LTD First Medical Center, Georgia","0180",{"type":74,"coordinates":265},[235,236],{"lat":236,"lon":235},{"facility":268,"status":67,"city":269,"state":44,"zip":270,"country":271,"countryCode":272,"cosmosGeoPoint":273,"geoPoint":277,"contacts":44},"HaEmek MC, Israel","Afula","1834111","Israel","IL",{"type":74,"coordinates":274},[275,276],35.2892,32.60907,{"lat":276,"lon":275},{"facility":279,"status":67,"city":280,"state":44,"zip":281,"country":271,"countryCode":272,"cosmosGeoPoint":282,"geoPoint":286,"contacts":44},"Barzilai MC, Israel","Ashkelon","7830604",{"type":74,"coordinates":283},[284,285],34.57149,31.66926,{"lat":285,"lon":284},{"facility":288,"status":67,"city":289,"state":44,"zip":290,"country":271,"countryCode":272,"cosmosGeoPoint":291,"geoPoint":295,"contacts":44},"Meir MC, Israel","Kfar Saba","4438164",{"type":74,"coordinates":292},[293,294],34.90694,32.175,{"lat":294,"lon":293},{"type":297,"investigatorFullName":44,"investigatorTitle":44,"investigatorAffiliation":44,"oldNameTitle":44,"oldOrganization":44},"SPONSOR","100614481","phase-2-a-study-to-investigate-the-clinical-effect-and-the-safety-of-prx-115-infused-intravenously-at-different-dosing-regimens-with-and-without-methotrexate-versus-placebo-in-adults-gout-patients-release-100614481",false,"NCT07280156","A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Efficacy, Safety, and Dosing Regimen Selection of Multiple Intravenous Infusions of PRX-115 With and Without Methotrexate Versus Placebo in Adult Patients With Gout (RELEASE)","RELEASE","Inclusion Criteria:\n\n1. Males or females ≥18 years of age.\n2. Weight within the range of 50.0 - 150.0 kg.\n3. Gout patients who failed to normalize sUA (\\\u003C7 mg\u002FdL) with or without xanthine oxidase inhibitors or uricosuric agent or have contraindications to these drugs.\n4. Willing to discontinue any oral ULT\n5. Females who are sterile, postmenopausal, or non-pregnant and using birth control methods.\n\nExclusion Criteria:\n\n1. Any condition known to have arthritis as a clinical manifestation.\n2. Positive testing for HBV,HCV, or HIV.\n3. The patient is a pregnant or lactating female or plans to become pregnant during the study period.\n4. Known allergy or sensitivity to the injected proteins, including pegylated products.\n5. Prior exposure to any experimental or marketed uricase.\n6. Patient treated with a medication known to have an influence on urate metabolism or clearance such as ULTs.\n7. History of anaphylaxis, severe allergic reactions, or severe atopy.\n8. G6PD deficiency or known catalase deficiency.\n9. History of significant hematologic or autoimmune disorders within 5 years of Screening and\u002For patient is immunocompromised or treated with immunosuppressive medications.\n10. Non-compensated CHF or hospitalization for CHF (Stage 3-4 NYHA Functional Class) within 3 months of the Screening Visit, uncontrolled arrhythmia, treatment for acute coronary syndrome (myocardial infarction or unstable angina), or uncontrolled BP (\\>160\u002F100 mmHg) at screening and prior to randomization at Week -4 (Visit 1).\n11. Current liver disease, as determined by ALT or AST levels above upper limit of normal at Screening Visit.\n12. Chronic liver disease.\n13. Hemoglobin \\\u003C11 g\u002FdL, neutrophil count \\\u003C1500 \u002Fµl, or platelet count \\\u003C100,000 \u002Fµl.\n14. Known severe pulmonary fibrosis, bronchiectasis or interstitial pneumonitis.\n15. eGFR ≤ 40 mL\u002Fmin\u002F1.73m2 tested at Screening Visit. Kidney transplant or requires dialysis.\n16. Known intolerance and\u002For known contraindication to MTX treatment or MTX treatment considered inappropriate\n17. Has uncontrolled type 2 diabetes at Screening with HbA1c ≥8.5%. Patients with type 1 diabetes will be excluded.\n18. Has known latent autoimmune diabetes of adult.\n19. Immunocompromised state, regardless of etiology.\n20. History or treatment of malignancy in the last 5 years, excluding localized, nonmelanoma skin cancers (e.g. basal or squamous cell)","ALL","18 Years",{"count":309,"type":310},150,"ESTIMATED","INTERVENTIONAL",[313],"PHASE2","This is a multicenter, randomized, double-blind, placebo-controlled phase II study assessing the efficacy, safety, and dosing regimen selection of multiple IV infusions of PRX-115 over 24 weeks, with or without MTX, versus the respective placebos in adult patients with gout.",[316],"Gout",[318,319,320,321,41],"gout","uricase","uric acid","hyperuricemia","2026-06-10",{"date":324,"type":325},"2026-06-11","ACTUAL",{"date":327,"type":325},"2025-12-22",{"date":329,"type":310},"2028-06",{"name":5,"class":6},27]